

Please type a plus sign (+) inside this box → ☐Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

Do not be used for all correspondence after initial filing)

Application Number	09/992,524
Filing Date	November 13, 2001
First Named Inventor	Vasquez, Maximiliano
Group Art Unit	1644
Examiner Name	G. Ewoldt
Attorney Docket Number	011823-008120US

Total Number of Pages in This Submission

9

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard Third Preliminary Amendment
--	---	---

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name	Townsend and Townsend and Crew LLP Joe Liebeschuetz	Reg. No. 37,505
Signature		
Date	February 6, 2003	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date:

February 6, 2003

Typed or printed name Paula Faulk Hurley

Signature

Date

February 6, 2003


Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3282157 v1

RECEIVED

FEB 13 2003

TECH CENTER 1600/2900





I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 011823-008120US

Assistant Commissioner for Patents
Washington, D.C. 20231

On January 14, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Paula Faulk Hurley

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Vasquez et al.

Application No.: 09/992,524

Filed: November 13, 2001

For: HUMANIZED ANTIBODIES TO
GAMMA-INTERFERON

Examiner: G. Ewoldt

Art Unit: 1644

THIRD PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please enter the following amendments and remarks.

IN THE SPECIFICATION:

Please replace the paragraph beginning on page 5, line 5 with the following rewritten paragraph:

Fig. 3: Comparison of the mature heavy chain variable region amino acid sequence of humanized immunoglobulin HuZAF, humanized immunoglobulin haf25, and humanized immunoglobulin HuXAF.

TECH CENTER 1600/2900

FEB 13 2003

RECEIVED

#5/c
Jm
3/15/03